Vaxcyte Inc [PCVX] stock is trading at $30.79, up 0.06%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PCVX shares have lost -4.65% over the last week, with a monthly amount drifted -9.31%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman started tracking the stock with Buy rating on December 20, 2024, and set its price target to $135. On December 07, 2023, Mizuho initiated with a Buy rating and assigned a price target of $69 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. Needham reiterated its recommendation of a Buy and raised its price target to $58 on January 03, 2023. Guggenheim started tracking with a Buy rating for this stock on December 15, 2022, and assigned it a price target of $66. In a note dated November 17, 2022, BTIG Research initiated a Buy rating and provided a target price of $69 on this stock.
Vaxcyte Inc [PCVX] stock has fluctuated between $27.66 and $121.06 over the past year. Currently, Wall Street analysts expect the stock to reach $124 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $30.79 at the most recent close of the market. An investor can expect a potential return of 302.73% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.17 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.35 points at the first support level, and at 29.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.21, and for the 2nd resistance point, it is at 31.62.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 11.11. Also, the Quick Ratio is 11.11, while the Cash Ratio stands at 1.99.
Transactions by insiders
Recent insider trading involved Eydelma Mikhail, SVP, GEN COUNSEL & CORP SEC, that happened on Mar 05 ’25 when 5000.0 shares were sold. Officer, Eydelma Mikhail completed a deal on Mar 05 ’25 to buy 5000.0 shares. Meanwhile, CHIEF OPERATING OFFICER Wassil Jim sold 8000.0 shares on Mar 03 ’25.
